BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/28/2018 10:31:14 AM | Browse: 947 | Download: 1529
 |
Received |
|
2018-04-10 09:50 |
|
Peer-Review Started |
|
2018-04-10 10:58 |
|
To Make the First Decision |
|
2018-04-27 02:08 |
|
Return for Revision |
|
2018-05-15 06:49 |
|
Revised |
|
2018-05-15 09:54 |
|
Second Decision |
|
2018-06-07 12:08 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-06-08 23:35 |
|
Articles in Press |
|
2018-06-08 23:35 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-09-16 09:10 |
|
Publish the Manuscript Online |
|
2018-09-28 10:31 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ozkan Kanat, Hulya Ertas and Burcu Caner |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Faculty of Medicine, Uludag University, Gorukle, Bursa 16059, Türkiye. ozkanat@uludag.edu.tr |
| Key Words |
Epidermal growth factor receptor; Cetuximab; Panitumumab; Human epidermal growth factor receptor 2; Anti-epidermal growth factor receptor resistance; Trastuzumab; Dual inhibition |
| Core Tip |
We reviewed the preclinical studies exploring the role of human epidermal growth factor receptor 2 (HER2) signaling in the development of anti-epidermal growth factor receptor therapy resistance in metastatic colorectal cancer and discussed the status of clinical trials assessing the activity of HER2 inhibitors in this setting. |
| Publish Date |
2018-09-28 10:31 |
| Citation |
Kanat O, Ertas H, Caner B. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World J Clin Cases 2018; 6(11): 418-425 |
| URL |
http://www.wjgnet.com/2307-8960/full/v6/i11/418.htm |
| DOI |
http://dx.doi.org/10.12998/wjcc.v6.i11.418 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
